Vermillion Delisted from Nasdaq; Will Trade on Pink Sheets

Sep 25, 2008

NEW YORK (GenomeWeb News) – Vermillion said today that it has been delisted from the Nasdaq Capital Market as of this morning due to noncompliance with Nasdaq’s minimum requirements.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Already have an account?
Login Now.

Breaking News

In Brief This Week: Interleukin Genetics, Quest Diagnostics, FDA, and More
IBM, JDRF Collaborate to Research Type 1 Juvenile Diabetes Risk Factors
People in the News: Eric Whitaker, Manohar Furtado, Kathy Hudson, More
Genome BC Invests in Program to Automate Cancer Sample Prep
Great Basin in Default of Senior Notes for $18.3M
Fluidigm Licenses NGS Library Prep Assay for Cystic Fibrosis Gene From Baylor Genetics

The Scan

Try the Other Version

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

You Do Your Way

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

CRISPR Discussions

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

This Week in Science

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.

Main menu